Hypofibrinolysis during induction treatment of multiple myeloma may increase the risk of venous thrombosis

Adriana M. W. van Marion; Johannes J. A. Auwerda; Monique C. Minnema; Rolinda van Oosterom; Jelle Adelmeijer; Philip G. de Groot; Frank W. G. Leebeek; Pieter Sonneveld; Henk M. Lokhorst; Ton Lisman

doi:10.1055/s-0037-1615590

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2005; 94(06): 1341-1343
DOI: 10.1055/s-0037-1615590

Letter to the Editor

Schattauer GmbH

Hypofibrinolysis during induction treatment of multiple myeloma may increase the risk of venous thrombosis

Authors

Adriana M. W. van Marion

¹ Department of Haematology, 2Department of Pathology, University

² Medical Centre Utrecht, 3Department of Haematology, Erasmus
Johannes J. A. Auwerda

³ Medical Centre Rotterdam
Monique C. Minnema

⁴ Department of Internal Medicine, Academic Medical Centre Amsterdam, The Netherlands
Rolinda van Oosterom

¹ Department of Haematology, 2Department of Pathology, University
Jelle Adelmeijer

¹ Department of Haematology, 2Department of Pathology, University
Philip G. de Groot

¹ Department of Haematology, 2Department of Pathology, University
Frank W. G. Leebeek

³ Medical Centre Rotterdam
Pieter Sonneveld

³ Medical Centre Rotterdam
Henk M. Lokhorst

¹ Department of Haematology, 2Department of Pathology, University
Ton Lisman

¹ Department of Haematology, 2Department of Pathology, University

Abstract

Volltext

Referenzen

References
1 Osman K, Comenzo R, Rajkumar SV. Deep venous thrombosis and thalidomide therapy for multiple myeloma. N Engl J Med 2001; 344: 1951-2.
2 Zangari M, Siegel E, Barlogie B. et al Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood 2002; 100: 1168-71.
3 Minnema MC, Fijnheer R, de Groot PG. et al Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment. J Thromb Haemost 2003; 1: 445-9.
4 Zangari M, Saghafifar F, Mehta P. et al The blood coagulation mechanism in multiple myeloma. Semin Thromb Hemost 2003; 29: 275-82.
5 Deitcher SR, Choueiri T, Srkalovic G. et al Acquired activated protein C resistance in myeloma patients with venous thromboembolic events. Br J Haematol 2003; 123: 959.
6 Carr Jr. ME, Dent RM, Carr SL. Abnormal fibrin structure and inhibition of fibrinolysis in patients with multiple myeloma. J Lab Clin Med 1996; 128: 83-8.
7 Yagci M, Sucak GT, Haznedar R. Fibrinolytic activity in multiple myeloma. Am J Hematol 2003; 74: 231-7.
8 Lisman T, de Groot PG, Meijers JC. et al Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. Blood 2005; 105: 1102-5.
9 Minnema MC, Breitkreutz I, Auwerda JJ. et al Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy. Leukemia 2004; 18: 2044-6.
10 Francis CW. Plasminogen activator inhibitor-1 levels and polymorphisms. Arch Pathol Lab Med 2002; 126: 1401-4.
11 Ridker PM, Vaughan DE, Stampfer MJ. et al Baseline fibrinolytic state and the risk of future venous thrombosis. A prospective study of endogenous tissuetype plasminogen activator and plasminogen activator inhibitor. Circulation 1992; 85: 1822-7.
12 Prins MH, Hirsh J. A critical review of the evidence supporting a relationship between impaired fibrinolytic activity and venous thromboembolism. Arch Intern Med 1991; 151: 1721-31.
13 Lisman T, Leebeek FW, Mosnier LO. et al Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology 2001; 121: 131-9.
14 Lisman T, Adelmeijer J, Nieuwenhuis HK. et al Enhancement of fibrinolytic potential in vitro by anticoagulant drugs targeting factor Xa, but not by those inhibiting thrombin or tissue factor. Blood Coag Fibrinol 2003; 14: 557-62.